NCT02509039View on ClinicalTrials.gov

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 2, 2015

Primary Completion Date

May 9, 2023

Study Completion Date

May 9, 2023

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

CC-122

5 continuous days out of 7 days per week intermittent dosing

Trial Locations (3)

1358550

Local Institution - 002, Koto-ku

464-8681

Local Institution - 003, Chikusa-ku

277-8577

Local Institution - 001, Kashiwa

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY